www.neurimmune.com Open in urlscan Pro
46.231.204.136  Public Scan

Form analysis
0 forms found in the DOM

Text Content

MAIN NAVIGATION

 * Careers
 * News
 * Contact


MAIN NAVIGATION

 * About us
   * About Neurimmune
   * Executive Committee
   * Board of Directors
   * Advisory Board
   * Our Business
   * Industry Partnerships
   * Academic Collaborations
   * Code of Conduct
   * Company History
   * Photography
   * Acknowledgments & Credits
 * Aducanumab
   * Amyloid Depletion
   * Discovery of Aducanumab
   * Further Information
 * Research & Development
   * Pipeline
   * Alzheimer’s Disease
   * Amyotrophic Lateral Sclerosis
   * ATTR Cardiomyopathy
   * Parkinson’s Disease
   * Type-2 Diabetes
   * Viral Diseases
   * Scientific Publications
 * Technology
   * RTM™ Technology Platform
   * Protein Aggregation Diseases




MAIN NAVIGATION

 * About us
   * About Neurimmune
   * Executive Committee
   * Board of Directors
   * Advisory Board
   * Our Business
   * Industry Partnerships
   * Academic Collaborations
   * Code of Conduct
   * Company History
   * Photography
   * Acknowledgments & Credits
 * Aducanumab
   * Amyloid Depletion
   * Discovery of Aducanumab
   * Further Information
 * Research & Development
   * Pipeline
   * Alzheimer’s Disease
   * Amyotrophic Lateral Sclerosis
   * ATTR Cardiomyopathy
   * Parkinson’s Disease
   * Type-2 Diabetes
   * Viral Diseases
   * Scientific Publications
 * Technology
   * RTM™ Technology Platform
   * Protein Aggregation Diseases

 * Careers
 * News
 * Contact




HOME

Learning from the memory of life

Learning from the memory of life

to develop transformative immune therapeutics



Neurimmune is a biopharmaceutical company translating human immune memory into
antibody therapeutics. Neurimmune scientists discovered aducanumab together with
a team of researchers at the University of Zurich. Neurimmune licensed
aducanumab to Biogen and collaborates with Biogen on its development. In 2021,
the U.S. FDA approved aducanumab for the treatment of Alzheimer’s disease.

About Neurimmune

Committed to promote independence in life

Committed to promote independence in life

by pioneering novel treatments

Aducanumab is a human monoclonal antibody against beta amyloid in development
for the treatment of Alzheimer’s disease. The U.S. FDA approved aducanumab for
the treatment of Alzheimer’s disease. In addition, Biogen has filed applications
for regulatory approval of aducanumab in other regions.

Aducanumab

Transforming the wisdom of life

Transforming the wisdom of life

into promising drug candidates

Besides aducanumab, Neurimmune’s scientists discovered cinpanemab for
Parkinson's disease, the anti-tau antibody BIIB076 for Alzheimer's disease, the
anti-miSOD1 antibody AP-101 for amyotrophic lateral sclerosis, and the anti-ATTR
antibody NI006 for cardiomyopathy. These programs are currently evaluated in
clinical trials.

Neurimmune pipeline

Decoding immune memories of life

Decoding immune memories of life

to develop therapeutic antibodies

By using Reverse Translational Medicine™ technology, Neurimmune’s scientists and
researchers translate genetic information of lymphocyte transcripts from elderly
human donors into therapeutic antibodies. Evolutionarily optimized and wisely
elected antibodies with preferred activities combine high affinity with target
selectivity, excellent pharmacodynamics and low immunogenicity.

RTM™ Technology Platform


SCIENTIFIC PUBLICATIONS

View all

N Engl J Med - 2023

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Read more

Sci Transl Med. - 2018

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms
in mouse models of amyotrophic lateral sclerosis

Read more

Nature - 2016

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Read more


NEWS

View all

12.10.2023 | Company News

Promising results for NI203, an experimental therapy depleting pathologic IAPP
aggregates to protect beta cell health, published in Nature Communications.

Read more

20.05.2023 | Press Release

Promising Phase 1 results for antibody NI006 in ATTR cardiomyopathy published in
The New England Journal of Medicine.

Read more

17.05.2023 | Company News

Primary results of its Phase 1b proof-of-concept study of NI006, a recombinant
human antibody to deplete amyloid deposits in ATTR cardiomyopathy, will be
presented in Prague at ESC Heart Failure Congress 2023, on May 20, 4:40 pm CEST.

Read more

Driven by the passion for life

Driven by the passion for life

to help patients around the world

Roger M Nitsch, MD

CEO

View details

Christoph Hock, MD

CMO

View details

Jan Grimm, PhD

CSO

View details



SITE FOOTER

 * About us
   * About Neurimmune
   * Executive Committee
   * Board of Directors
   * Advisory Board
   * Our Business
   * Industry Partnerships
   * Academic Collaborations
   * Code of Conduct
   * Company History
   * Photography
   * Acknowledgments & Credits
 * Aducanumab
   * Amyloid Depletion
   * Discovery of Aducanumab
   * Further Information
 * Research & Development
   * Pipeline
   * Alzheimer’s Disease
   * Amyotrophic Lateral Sclerosis
   * ATTR Cardiomyopathy
   * Parkinson’s Disease
   * Type-2 Diabetes
   * Viral Diseases
   * Scientific Publications
 * Technology
   * RTM™ Technology Platform
   * Protein Aggregation Diseases

 * Neurimmune AG
   * 8952 Schlieren / Zurich
   * Switzerland
   * T: +41 44 755 46 46
   * Media contact
   * Location in Google maps



Neurimmune © 2023

 * Legal notice
 * Privacy Policy

This website uses cookies, with the aim of ensuring that you have the best
possible online experience. In using our website, you are giving your consent to
the terms and conditions of our Privacy policy

Close

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue